News Releases
Bachem News & Events
Learn more about what is happening at Bachem, what activities we have coming up, and what events you can meet us both virtually and in-person.
More News Releases by Bachem
More Content From Bachem
-
This webinar will focus on Bachem's approach to execute the risk assessment for peptides produced by SPPS
-
Bachem is the world’s leading company in the development and production of peptides and oligonucleotides (TIDES).
-
Interest in oligonucleotide therapeutics has grown, as has the market demand, since their emergence as a new drug modality two decades ago.
-
Oligonucleotides are very promising and versatile therapeutics for rare and genetic diseases.
-
-
Emerging as a new treatment option in rare and orphan disease areas, oligonucleotides have matured into a drug class with a broad indication spectrum.
-
What ingredients make Bachem a world-leading specialist for drug substances and a partner for pharma & biotech across the globe?
-
Secrets of an important byproduct revealed
-
Interview with Seamus White
-
This webinar which will take you through the foreseeable future of peptides and oligonucleotides.
-
Partnering with a specialized CDMO can have many advantages especially for complex API like peptides or oligonucleotides.
-
Peptides are very interesting molecules for many applications from therapeutics to cosmetics and diagnostics. But how are they made?
-
Liraglutide, a so-called glucagon like peptide-1 (GLP-1) receptor agonist, is used for the treatment of Type 2 diabetes mellitus and obesity.
-
Bachem covers the entire life cycle of an active pharmaceutical ingredient (API). View all of our generic APIs here.
-
The use of nanoparticles for delivering proteins and peptides are still in early stages of development and is expected to mature in the near future.
